Natera, Inc. - Common Stock (NQ:NTRA)

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Natera (NASDAQ:NTRA) and the...

Topics Economy

Spotting Winners: Natera (NASDAQ:NTRA) And Immuno-Oncology Stocks In Q3

November 19, 2025

Topics Artificial Intelligence

Employees Volunteer Over 1,500 Hours During Natera’s Annual Volunteer Month

November 19, 2025

Druckenmiller Opens Position In Amazon, Closes Microsoft — Here's More Of Duquesne's Biggest Q3 Moves ↗

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

November 14, 2025

Stanley Druckenmiller's Duquesne Family Office Q3 13F reinforces the firm's reputation for agile and opportunity-driven asset allocation.

Via Benzinga

Natera Integrates with Flatiron Health’s OncoEMR® Platform

November 12, 2025

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have caused the...

1 Healthcare Stock with Impressive Fundamentals and 2 Facing Headwinds

November 11, 2025

The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro...

Topics Stocks

2 Surging Stocks with Impressive Fundamentals and 1 We Question

November 10, 2025

Natera (NTRA) Q3 2025 Earnings Call Transcript

Natera (NTRA) Q3 2025 Earnings Call Transcript ↗

November 09, 2025

Via The Motley Fool

Topics Earnings

NTRA Q3 Deep Dive: Oncology Momentum and New Product Expansion Drive Guidance Increase

November 07, 2025

Genetic testing company Natera (NASDAQ:NTRA). beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 34.7% year on year to $592.2 million. The company’s full-year revenue guidance of $2.22...

Natera Inc (NASDAQ:NTRA) Q3 2025 Earnings: Revenue Soars Past Estimates, Shares Climb on Raised Guidance ↗

November 06, 2025

Natera (NTRA) Q3 2025 results beat revenue forecasts with $592.2M, driven by strong oncology test growth. The company raised its full-year 2025 guidance.

Via Chartmill

Natera (NASDAQ:NTRA) Delivers Impressive Q3

November 06, 2025

Genetic testing company Natera (NASDAQ:NTRA). reported Q3 CY2025 results beating Wall Street’s revenue expectations, with sales up 34.7% year on year to $592.2 million. The company’s full-year revenue...

Natera Reports Third Quarter 2025 Financial Results

November 06, 2025

Genetic testing company Natera (NASDAQ:NTRA). will be reporting earnings this Thursday after the bell. Here’s what to expect.

Natera (NTRA) Reports Earnings Tomorrow: What To Expect

November 04, 2025

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps...

Topics Artificial Intelligence

November 02, 2025

Natera Announces Expansion to 20 Genes for its Fetal Focus™ Single-Gene NIPT

October 31, 2025

Natera to Report its Third Quarter Results on November 6, 2025

October 30, 2025

Natera Reports Strong Advanced Adenoma Data from Prospective PROCEED-CRC Trial, Demonstrating 22.5% Sensitivity and 91.5% Specificity

October 28, 2025

Halper Sadeh LLC Encourages Natera Inc. Shareholders to Contact the Firm to Discuss Their Rights

October 27, 2025

From Halper Sadeh LLC

As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the immuno-oncology industry, including Natera (NASDAQ:NTRA) and its peers.

A Glimpse Into The Expert Outlook On Natera Through 8 Analysts ↗

October 23, 2025

Via Benzinga

Reflecting On Immuno-Oncology Stocks’ Q2 Earnings: Natera (NASDAQ:NTRA)

October 20, 2025

Shares of genetic testing company Natera (NASDAQ:NTRA). jumped 7.2% in the afternoon session after the company announced promising results from its phase 3 IMvigor011 clinical trial for its Signatera...

Topics Artificial Intelligence

Why Are Natera (NTRA) Shares Soaring Today

October 20, 2025

Successful IMvigor011 Trial Achieves 41% Improvement in Overall Survival for Bladder Cancer Patients

Topics Intellectual Property

October 20, 2025

Natera Named to Fast Company’s Next Big Things in Tech List

October 16, 2025

Here's How Much $1000 Invested In Natera 5 Years Ago Would Be Worth Today ↗

October 13, 2025

Via Benzinga

Natera to Host Investor Call on October 23, 2025 to Discuss ESMO Findings

October 13, 2025

Natera to Present 14 Studies at ESMO, Including IMvigor011 Oral Presentation in Presidential Symposium

October 12, 2025

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because...

2 of Wall Street’s Favorite Stocks on Our Watchlist and 1 That Underwhelm

October 06, 2025

Topics Retirement

Enrollment Tops 1,600 in Natera’s EXPAND Trial of Single Gene NIPT

October 01, 2025

Natera Announces Publication of Signatera™ Validation Study in Testicular Cancer

September 30, 2025